증례 : 신장 ; 관상동맥 성형술 시행한 환자에서 Clopidogrel과 관련된 용혈성 요독증후군 = Case Reports : Nephrology ; Hemolytic Uremic Syndrome with Clopidogrel after Coronary Angioplasty

국문 초록 (Abstract)

Clopidogrel은 항혈소판제로 여러 임상영역에서 사용된다. 기존의 약제보다 부작용도 적어 안전하게 널리 쓸 수 있는 이 약제가 드물게는 이와 같은 심각한 합병증을 유발할 수 있다. 이에 우리는 이러한 합병증을 이해하고 주의 해야 한다. 저자들은 급성 관상동맥 증후군이 있었던 47세 남자 환자에서 이와 같은 합병증을 경험하였고, 약물 중단 및 치료적 혈장분리술 등으로 호전되었던 증례를 1예 경험하였기에 문헌고찰과 함께 보고하는 바이다.

다국어 초록 (Multilingual Abstract)

Thienopyridines are antiplatelet agents used in post-percutaneous coronary angioplasty patients and patients with acute coronary syndrome, stroke, and peripheral arterial disease. Ticlopidine has been shown to reduce the incidence of stent thrombosis, but it may also cause serious hematological side effects. Among the thienopyridines, clopidogrel is considered to be a safe alternative to ticlopidine because of its decreased incidence of hematological adverse effects. However, some hematological side effects can occur and may be fatal. In this case, a 47-year-old man complained of dyspnea and generalized edema. He had been taking clopidogrel after coronary angioplasty. His laboratory findings showed acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia, which were consistent with hemolytic uremic syndrome (HUS). After discontinuing clopidogrel and undergoing plasma exchange, he recovered fully. To our knowledge, this is the first reported case of clopidogrel-induced HUS in Korea. (Korean J Med 2011;80:S253-S257)

참고문헌 (Reference)

1 Amorosi EL, "Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature" 45 : 139-160, 1966

2 Bennett CL, "Thrombotic thrombocytopenic purpura associated with clopidogrel" 342 : 1773-1777, 2000

3 Mehta SR, "The clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease" 21 : 2033-2041, 2000

4 Gasser C, "Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia" 85 : 905-909, 1955

5 Balamuthusamy S, "Hematologic adverse effects of clopidogrel" 14 : 106-112, 2007

6 Steinhubl SR, "Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial" 288 : 2411-2420, 2002

7 Bertrand ME, "Doubleblind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)" 102 : 624-629, 2000

8 Majhail NS, "Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality" 70 : 466-470, 2003

9 Herbert JM, "Biochemical and pharmacological properties of clopidogrel: a new ADP receptor antagonist" 1 : A31-A40, 1999

10 Diener HC, "Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial" 364 : 331-337, 2004

11 Sabatine MS, "Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation" 352 : 1179-1189, 2005

12 CAPRIE steering committee, "A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) CAPRIE Steering Committee" 348 : 1329-1339, 1996